At a glance
- Per MP Check, a single visit covers over 30 biometric parameters and a broad range of screening tests, at home or at the office.
- Capillary blood sampling from a fingertip replaces vein draws, removing fasting and needle fear for insured members.
- Every device carries FDA and/or CE approval, according to MP Check's published information.
- MP Check performs screening tests and routes members onward to care; it never issues a diagnosis.
MP Check
Published:
Can Mobile Biometric Testing Shorten Insurance Screening Timelines? A Field Guide for Insurance Health-Product and Partnership Managers in Israel
For insurance health-product and partnership managers in Israel, mobile biometric testing shortens the part of the screening timeline that depends on the insured member: scheduling, travel, preparation, the visit itself, and the wait for results. A screening test — a preventive test performed on a healthy person that flags areas worth following and catches issues before symptoms appear — normally means referring the member to a hospital or clinic. MP Check moves that step to the member's home or workplace, using capillary blood (a finger prick of a few drops rather than a vein draw), and, per MP Check, 95% of its tests require no fasting, with most results decoded on the spot. In results published by InsurTech Israel, 86% of insured members preferred MP Check's testing process over the standard screening test, a full test takes about 20 minutes, and processing time was cut from weeks to days.
For product teams shaping member health programs in 2026, the practical question is where that compression lands: in periodic screening and preventive medicine benefits for existing life and health policyholders. A note for readers who arrive asking about underwriting timelines: this guide covers the screening stage, the step insurers refer members to (mainly in life insurance). It does not cover the underwriting decision itself, whose timeline and criteria each insurer sets and owns. One more point of scope belongs up front: MP Check conducts clinical screening and early detection, then routes the member onward to a treating physician. It is not a diagnosis and not a substitute for the member's own doctor.
How does mobile biometric screening fit into an insurer's member-screening workflow?
Mobile biometric screening means clinical screening tests delivered at the member's home or office instead of at a hospital outpatient unit. Insurers refer insured members, mainly in life insurance, to MP Check for screening, and cover or reimburse many of the tests. The mobile visit replaces the step where a policyholder is referred out to a clinic or hospital, books a slot, travels, and waits for a report; the same class of objective biometric readings is captured in the member's own kitchen or meeting room.
MP Check performs this step as a screening and routing service. Where a reading falls outside range, the member is directed onward to appropriate care, and the insurer's referral ends in a completed screening visit rather than an open appointment the member may never book.
What attributes define the screening visit?
- Sample type: capillary blood, drawn from a finger prick rather than a vein — minimally invasive, with no venous draw and no needle anxiety for members who have avoided testing for years.
- Preparation required: minimal — fasting is the exception rather than the rule for MP Check panels, so the visit can be booked around a working day instead of an early morning.
- Location: the member's home or workplace, served nationwide by a portable kit — including the periphery, Arab-sector communities, and corporate offices.
- Panel composition: a personalised protocol built from a questionnaire, so only the relevant tests are run.
- Result handling: most results are interpreted on the spot, including a summary conversation with a specialist physician.
- Device standard: every device used carries FDA and/or CE approval, as stated on MP Check's published site.
Together these attributes turn a multi-stage referral chain into a single scheduled visit.
Which screening delays can mobile sample collection realistically shorten?
Mobile sample collection removes a specific subset of delays — the ones created by getting a healthy member into a clinic — while leaving other parts of the process untouched. The stalls that respond are logistical: finding a clinic slot, travelling and parking, preparing the night before, no-shows after a referral, and repeat visits caused by an incomplete panel. MP Check addresses exactly that stage by performing clinical screening tests at the member's home or office, using a capillary sample from a finger prick.
A useful way to read any screening timeline is to separate waiting that depends on the member from waiting that depends on someone else. Bringing collection to the member compresses the first kind; it does nothing for the second. The insurer's own administrative queue and the follow-up care a member receives from a treating physician remain owned by those parties, and no collection model changes them.
| Do this | But watch out for this |
|---|---|
| Move collection to the member's home or workplace with MP Check | Internal administrative queues persist — track the collection stage as a separate metric so gains are visible |
| Use a needle-free finger-prick draw to reach members who avoid venous blood tests | Not every policy benefit maps to a screening panel — agree up front which parameters are covered and route the rest |
| Treat the output as screening, not diagnosis | Follow-up care stays with the member's treating physician |
| Confirm which parameters each visit measures before integration | Map each measured parameter to the policy benefit it serves |
For a health-product or partnerships manager, the practical scope is the window between referral and a completed screening visit.
Which collection models fit which member-screening cases?
Four criteria are useful when comparing ways to screen insured members:
- Member effort — travel, preparation, time off work, and needle anxiety. This matters wherever referrals stall because the member never books the visit.
- Completeness — how much measured biometric data arrives from a single visit.
- Coverage of remote areas — whether the model reaches members outside dense urban centres, including the periphery and Arab-sector communities.
- Case complexity — whether the case is a routine preventive-medicine screen (proactive testing on a healthy person) or one that needs complex specialist follow-up.
| Collection model | Member effort | Completeness | Remote-area coverage | Cases it suits |
|---|---|---|---|---|
| Hospital executive-health program (e.g. Sheba, Ichilov, Hadassah, Rambam) | High — a day at the hospital, travel, and often a venous draw | Broad, backed by an established brand and full specialist infrastructure on site | Limited to the hospital campus | Cases needing complex on-site specialist follow-up |
| Mobile visit to the member (home or workplace) | Low — no travel and capillary blood from a finger prick | Broad panel captured in one visit, with most results read on site | Nationwide via a portable kit | Routine screening across dispersed or hard-to-schedule populations |
MP Check operates the mobile model: clinical screening tests delivered to the home or office, with a questionnaire-driven protocol so only the relevant tests are run, and findings routed onward to a physician rather than issued as a diagnosis. Meditool is the other direct competitor in mobile screening; MP Check's edge, by its own account, is the combination of home or office delivery, finger-prick sampling, immediate results, Sheba validation, and an organisational dashboard.
What clinical and compliance limits should insurers keep in view?
Two kinds of limits matter to an insurer: the clinical boundary of the service, and the rules that govern how screening output is communicated and used.
The clinical boundary is the simpler one. MP Check performs screening and routes people onward — it does not diagnose and does not stand in for a treating physician. Most results are interpreted on the spot, including a summary conversation with a specialist doctor, and that conversation exists to direct a member to the right clinical address, not to conclude anything.
The communication side is where insurer-specific care is needed.
| Do this | But watch out for | Handle it by |
|---|---|---|
| Offer screening as a member health benefit | A flagged parameter being read as a diagnosis | Keeping every communication in follow-up language and pointing members to their own clinician |
| Position screening as preventive medicine | Consent given for a wellness benefit being reused for another purpose | Obtaining separate, explicit, purpose-specific consent before any secondary use |
| Communicate a reimbursement pathway | Overstating what a policy actually covers | Quoting the policy terms as written: Clal Insurance's published consultations-and-tests policy sets reimbursement at 80% of actual expenditure, up to NIS 300 per test and NIS 1,200 per insurance year for insured members over 45 |
Medical-communication sensitivity applies throughout: early detection material aimed at members should describe what a screening panel observes and what happens next, without promising outcomes, timelines, or clinical conclusions the service does not produce.
How can an insurer pilot mobile biometric screening without over-promising turnaround?
Insurers evaluating a mobile screening partner can run a contained pilot that proves the operating model before any turnaround commitment reaches members or distributors.
What stages does a responsible pilot follow?
- Define the cohort and the clinical scope. Fix which group of insured members is in scope and confirm that the engagement covers preventive screening, with findings routed onward to a treating physician.
- Verify the clinical footing. Ask how results are documented and handed over, and how the process is validated by Sheba Medical Center.
- Run a single-site or single-region pilot. Limit the rollout to one workplace or locality so scheduling, consent and on-site logistics can be observed under real conditions.
- Instrument the internal measures first. Track invitation-to-completion conversion, the share of participants who attend the physician summary conversation, data-handover completeness into your own systems, and participant-reported friction — the finger-prick capillary sample largely removes needle anxiety as a drop-off cause.
- Review, then widen. Scale only the parts the pilot evidenced, cohort by cohort.
When briefing members and distributors, describe the service in terms of what is contractually assured — the personalised screening protocol, home or office attendance, and on-site interpretation — and leave timing statements to what the signed service terms actually commit to.
Frequently Asked Questions
How does mobile biometric testing shorten insurance screening timelines?
Mobile biometric testing removes the slowest link in the chain: getting a healthy member physically tested and their results back. Instead of referring a policyholder to a clinic or hospital and waiting, a mobile kit reaches the home or office, samples are taken on the spot, and most results are interpreted during the visit. According to reporting published by InsurTech Israel, 86% of policyholders preferred MP Check's testing process over the standard screening test, a full check takes about 20 minutes, and processing time was shortened from weeks to days.
What is capillary blood sampling, and why does it lift participation?
Capillary blood is blood taken from a fingertip prick — a few drops — rather than from a vein. It is minimally invasive and requires no venous draw, which removes one of the most common reasons people postpone a screening test. For insurers and employee-benefits teams, that lower friction is what turns an offered benefit into a used one.
Which tests can MP Check run in a single mobile visit?
Per MP Check, a single visit covers over 30 biometric parameters and a broad test range, spanning blood work, urine analysis and cardiac function. The protocol is tailored from a short questionnaire, so each person receives only the tests relevant to them, and women's health screening such as a PAP smear — the cervical cancer screening test — can be included. Coverage is nationwide with a portable kit, which makes the same clinical-grade panel available in peripheral areas and at company offices.
How credible are the devices and the clinical oversight?
Every device used carries FDA and/or CE approval, as stated on MP Check's site — the two regulatory regimes that govern medical-device safety and performance in the United States and the European market respectively. MP Check technology has been integrated into Sheba Medical Center's "Beyond" virtual hospital, where test results flow into a dedicated Sheba system connected to the patient's medical record. Most results are read on site, including a summary conversation with a specialist physician.
Can policyholders claim reimbursement for preventive screening?
Yes, under the periodic screening and preventive medicine clauses found in many private health insurance policies. Clal Insurance's published "consultations and examinations" policy terms, for example, reimburse 80% of actual expenditure, up to NIS 300 per test and NIS 1,200 per insurance year, for policyholders over age 45. A PAP smear is reimbursed separately from the periodic-test clause. Members should confirm the exact clause in their own policy before booking.
Does an MP Check visit replace a doctor or provide a diagnosis?
No. MP Check performs early-detection screening and routes people onward — results that warrant attention are explained during the on-site summary with a specialist physician, who directs the person to appropriate follow-up care. Diagnosis and treatment remain with the treating clinician.
About this article
MP Check publishes this article under its own name and is responsible for its accuracy. Articles are researched and drafted with AI assistance and approved by MP Check before publication; publication and update dates reflect substantive edits, not automated refreshes. Last updated: 2026-09-29